Products for Research Use Only

Gardiquimod (diTFA)

CAT: 0804-HY-103697A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-103697A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
CAS Number
1159840-61-5
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Gardiquimod_trifluoroacetate.html
Purity
99.0
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)
Smiles
OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.FC(C(O)=O)(F)F.FC(C(O)=O)(F)F
Molecular Formula
C21H25F6N5O5
Molecular Weight
541.44
Precautions
H302, H315, H319, H335
References & Citations
[1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7 (5) :381-8.|[3]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HIV-1; TLR7; TLR8